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The preparation of galactofuranosyl-containing disaccharidic parts of natural glycoconjugates was performed according to a chemo-
enzymatic synthesis. Our goals were firstly to develop an alternative approach to standard chemical strategies by limiting number of 
reaction and purification steps, and secondly to evaluate the scope of the Araf51 biocatalyst to transfer a galactofuranosyl moiety to a set 
of pyranosidic acceptors differing from each other by the series, the anomeric configuration as well as the conformation. The study of 
binding mode of the resulting disaccharides was also performed by molecular modeling and showed significant differences between 
(1→2)- and (1→6)-linked disaccharides. 
Introduction 
The complex heterogeneity of carbohydrates in living systems is a direct result of several carbohydrate characteristics: the ability of 
different types and numbers of sugar residues to form glycosidic bonds with one another, the type of anomeric linkage, the position and 
the absence or presence of branching, the more or less flexible conformations of the resulting oligo-, polysaccharides or 
glycoconjugates,1, 2 and the size of the monosaccharidic ring.3, 4 Indeed, sugars exhibit significant differences depending on whether they 
are present as pyranosides or as furanosides. It is now well established that the importance of the furanose ring in biology can no more be 
understated. A key characteristic of furanose ring systems is their higher flexibility compared to that of their pyranosidic counterparts,5 
and this profoundly influences their role in biological processes.6 While furanosyl-containing oligosaccharides are crucial constituents of 
surface glycoconjugates in cell walls of bacteria,7-9 fungi10 and parasitic11, 12 microorganisms, including some clinically significant 
pathogens, with an exception of 2-deoxy-D-ribose and D-ribose, furanosides are completely absent from mammals. This makes them 
interesting targets for development of new therapeutics. 
 A major limitation preventing the use of oligosaccharides as therapeutics is the difficulty in producing sufficient amount of these 
molecules in a desired purity. The isolation of these compounds from biological sources tends to be low yielding and presents the risk of 
contamination from infectious agents.13 Although a big progress in chemical synthesis of oligosaccharides has been made14-20 and 
synthesis of docosanaarabinofuranoside realized by Lowary’s research team21 is impressive evidence, this approach still remains a 
challenge. The chemical synthesis requires the stereo- and regioselective control of glycosidic bond formation, thus multiple protection 
and deprotection schemes are needed to achieve the required selectivity. Low yields of the desired products are also a result of the 
difficulty in purifying the deprotected compound along with product loss during each step of a multistep synthesis.13, 22 Nature's solution 
to the assembly of glycosidic bonds is the enzyme machinery belonging to the families of glycosyltransferases and of glycosidases. 
These enzymes have therefore enormous potential for the synthesis of biologically relevant carbohydrate structures.23 These biocatalysts 
offer a significant advantage over their chemical counterparts in their ability to form a specific glycosidic linkage in the presence of other 
reactive functional groups.22  
 In this context, only few groups are interested in the chemo-enzymatic synthesis of furanosyl-containing conjugates.3, 24-27 Furanosyl 
transferases are however rare and require both nucleotide-diphospho (NDP)-sugars as donors and suitable acceptors.28-30 Another 
approach, recently proposed by Thorson, is based on the glycosyl transferase reversibility, that uses simple glycosides as precursors of 
NDP-sugars for further transfer onto more complex natural products.31, 32 To the best of our knowledge, this strategy was not applied for 
the synthesis of furanosides. Recently, our team developed an enzyme-based protocol for the preparation of di- and oligofuranosides 
using the thermophilic Araf51 as biocatalyst.33 Considering structural similarity between L-arabino- and D-galactofuranosyl (D-Galf) 
entities, and the wide presence of D-Galf residues in natural glycoconjugates and polysaccharides, we now propose to expand the chemo-
enzymatic methodology to transglycosylation reactions in order to transfer a galactofuranosyl entity to a variety of pyranosidic acceptors 
(Figure 1). These substrates were chosen so as to perform the synthesis of furanosyl-pyranoside sequences relevant to pathogenic 
microorganisms3 as well as to estimate the specificity of this enzyme towards carbohydrate acceptors. As we expected that such 
pyranosides resist to hydrolysis by the furanosidase Araf51, the presence of the pNP group in the anomeric position was envisaged to 
enable simple UV detection of reaction products. Moreover, the D-gluco- (D-Glcp), D-galacto- (D-Galp) and D-mannopyranosidic (D-
Manp) epimers, as well as their anomeric configurations, offer stereochemical variations that may influence the fate of the coupling 
process. Finally, we made a focus on the L-rhamnopyranoside (L-Rhap) 8 for structural and biological reasons but also because it 
displays a 1C4 conformation instead a 
4C1 one observed for other acceptors 2-7. 
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Fig. 1 Structure of glycosyl donor 1 and acceptors 2-8. 
Results 
At the first place, unavailability of -1 subsite of Araf51 to pyranosidic acceptors was confirmed spectrophotometrically (405 nm) by 
incubation of individual pNP pyranosides 2-8 with the enzyme for 2 h at 60 °C in a phosphate buffer at pH 7.4. No release of p-
nitrophenolate was recorded, indicating that these compounds cannot act as donors, thus confirming our first hypothesis. Subsequently, to 
screen enzyme readiness to catalyze transglycosylation, individual analytical-scale reactions were performed starting from donor 1 and 
each of pNP glycopyranoside, and in the presence of Araf51. Thin layer chromatography monitoring showed the formation of 
disaccharides when the donor 1 was incubated with an equal molar quantity or with a 5-fold molar excess of pyranosidic acceptor, after 
only short incubation periods (5-20 min). These compounds resulted from both self-condensation of 1 and desired transglycosylation 
reactions. 
 As a model of biocatalyzed coupling, the progress of the reaction of 1 with 2 (pNP -D-Glcp) was monitored by HPLC (Figure 2). 
Between 5 and 20 minutes, digalactofuranosides constituted the main reaction products.33 At the same time, these products of self-
condensation were hydrolyzed more rapidly than furanosyl-pyranoside disaccharides, which resisted to hydrolysis for more than 3h. This 
could be explained by the structures of the resulting disaccharides which significantly differ from those of natural substrates of the 
enzyme. In the present model reaction, traces of trisaccharides were observed from the early stage of the reaction (5-10 min) and 
confirmed by mass spectrum analysis, but precise structures could not be elucidated. Importantly, when the ratio donor/acceptor was 
increased to 1:10, no products of self-condensation were detected. Moreover, synthesis of furano-pyrano-disaccharides was strongly 
favored over hydrolysis of 1. After careful chromatographic purification, two main disaccharides 9 and 10 were isolated and their 
structures were elucidated by NMR spectroscopy. The major product 9 was obtained in the yield of 44%. It exhibited an intense three-
bond coupling in the 13C-1H (HMBC) spectrum between H-1’ (5.09 ppm) and C-2 (79.2 ppm) as well as C-1’ (109.4 ppm) and H-2 (3.69 
ppm) and was identified as pNP β-D-galactofuranosyl-(1→2)-α-D-glucopyranoside 9 (Figure 2). The second regioisomer, isolated in 
34% yield, presented a correlation between H-1’ (5.24 ppm) and C-3 (79.4 ppm) as well as between C-1’ (108.3 ppm) and H-3 (3.96 
ppm). The compound was identified as (1→3)-linked disaccharide 10. The time-course analysis monitored by HPLC revealed that the 
(1→3)-disaccharide 10 was kinetically synthesized, followed by the formation of the (1→2)-isomer 9. This monitoring also showed that 
these compounds disappeared with times in favor of a third regioisomer. The yield of the latter culminated after 4 hours of reaction and it 
was still present after 24 hours. The precise nature of the corresponding glycosidic linkage could however not be clearly elucidated. As a 
result, the overall yield of transglycosylation reach a maximum, slightly greater than 80%, between 5 and 20 minutes. In the present 
model reaction, traces of trisaccharides were observed from the early stage of the reaction (5-10 minutes) and confirmed by mass 
spectrum analysis, but precise structures could not be elucidated. 
 Under similar conditions, using the -glucopyranoside 3 as an acceptor (Figure 2), and after 20 minutes of reaction, three 
disaccharides were chromatographically separated: pNP β-D-Galf-(1→2)-β-D-Glcp 11, pNP β-D-Galf-(1→3)-β-D-Glcp 12, and pNP β-D-
Galf-(1→6)-β-D-Glcp 13 were isolated in 26%, 25% and 30% yields, respectively. The time-course analysis revealed that the (1→2)-
linked regioisomer 11 was the major kinetic product and is present together with the (1→3)-linked regioisomer 12 from the first minutes 
of the reaction. From about 15 minutes, the (1→6)-linked regioisomer 13 was formed and became the prevalent one after 1 hour. It was 
detected also with 15% yield after 24 hours. It is interesting to note that, when 12 was incubated with the biocatalyst and an excess of 3, 
it was transformed into 13. This emphasizes the striking stability of this (1→6)-bond in the presence of the furanosyl hydrolase Araf51. 
  To go further with this methodology, we applied the Araf-51-assisted synthesis of furanosyl-containing disaccharides to three other 
families of acceptors. The use of galactosidic acceptors 4 and 5 did not fundamentally change the observations previously exposed with 
the gluco series. Three disaccharides with (1→2)- (14), (1→3)- (15), and (1→4)-linkage (16) were obtained from the -anomer 4 and 
isolated in 73% overall yield (Table 1, entry 1). Substrate 5, characterized by a -configuration, afforded only the (1→2)- (17) and 
(1→6)-disaccharides (18) in a near equimolecular ratio and in a 52% overall yield (entry 2). 
 On another hand, the reaction with the -mannopyranoside 6 (entry 3) was relatively rapid compared to other pyranosidic acceptors 
and the degree of hydrolysis of formed disaccharides was slightly higher. The reaction in a preparative scale was thus carried out for only 
10 minutes. pNP β-D-Galf-(1→6)-α-D-Manp 19 was obtained in 15% yield. 2-D NMR analyses confirmed that three other regioisomers 
were obtained in a mixture in the overall yield of 43%. The time-course analysis monitored by TLC revealed that these regioisomers are 
readily formed from the first minutes of reaction with the maximal yields between 5 and 10 minutes. The (1→6)-linked regioisomer 19 
was formed from about 5 minutes of reaction. 
 
 
Fig. 2 Progress of the reaction of 1 with 2 or 3 catalyzed by Araf51. 
 The transglycosylation with the -anomer 7 was apparently slower than that of the α-anomer and the conversion of pNP β-D-Galf still 
did not reach maximum after two hours of reaction. However, the degree of hydrolysis was quite low, similarly to the other pNP 
pyranosides. After 25 minutes of the preparative-scale reaction, two regioisomers were isolated (entry 4). pNP β-D-Galf-(1→4)-β-D-
Manp 20 was obtained in a very high yield of 49%. The second regioisomer 21, identified as the (1→6)-disaccharide, was isolated in 
16% yield. The time-course analysis confirmed kinetic preferences for the (1→4)-linked disaccharide 20. In about 40 minutes of 
reaction, both regioisomers were present equivalently. At the end of 2 hours incubation, the favoured (1→6)-linked regioisomer 21 
prevailed. Structures were unambiguously established according to NMR data. 
 Finally, we also studied the L-rhamnopyranoside 8 since it presents a significantly different reactivity and because it is widely found in 
Nature. While three disaccharides were observed after 20 minutes of the biocatalytic process, exclusively one regioisomer 22, 
characterized by a (1→4)-connection, was indeed isolated and in a fairly good 38% yield (entry 5). Evidence of the precise structure was 
established on the basis of NMR data. More specifically, the C-4 signal in the starting substrate 8 (C-4=71.4 ppm) was shifted to 77.8 
ppm within the disaccharide 22, thus demonstrating the (1→4)-coupling, and this result was corroborated by 2D NMR experiments. 
Discussion 
All results obtained for the transfer of a galactofuranosyl residue to pyranosidic acceptors mediated by the arabinofuanosidase Araf51 
underline the ability of this enzyme to accept within its +1 sub-site all the seven tested pyranosidic acceptors. Importantly, the anomeric 
configuration of the latter modulated the behavior of the furanosyl transfer. Usually, the (1→2)-disaccharides were the most common in 
the gluco and galacto series, and readily formed and stable. The (1→3) linkage was formed subsequently and was also frequently 
presented in these series. Interestingly, none of these -anomers displayed the (1→6)-connection although for the -anomers, it 
represents the major thermodynamically formed linkage. In Nature, exo-acting -L-arabinofuranosidases release the arabinosyl 
decorations at C-2 and C-3 position of arabinogalacatans and arabinoxylans from a range of plant structural polysaccharides, where both 
the galactose and xylose moieties are presented in a -D-pyranose form. Thus, considering the structural similarity of xylose and glucose, 
kinetic or 
ermodynamic disaccharide with a very low quantity of the other regioisomer with respect to the time-course of the reaction. 
 
the transglycosylation preferences correspond to the hydrolytic activity on natural substrates. 
 Starting from -D-mannopyranoside and -L-rhamnopyranoside, the kinetically preferred linkage was the (1→4). It results from this 
observation that the adopted conformations within the active site of Manp and Rhap derivatives vary to some extent compared to the 
glucosidic and galactosidic monosaccharides. Thus the axial C-2 hydroxyl group in mannose, in contrast to glucose, seems to impact the 
conformation within the active site more markedly than the orientation of C-4 OH group distinguishing glucose from galactose. Overall, 
in all the three series where both anomers were tested (D-Glcp, D-Galp, D-Manp), the reactions involving the -anomer proceeded 
markedly faster than those of their -anomeric counterparts. The time-course analyses also revealed the crucial effect of the reaction time 
on the ratio of regioisomers formed in individual reactions. Thus, in most of cases, it is possible to isolate either 
th
Table 1 Araf51-mediated sy es identified in individual nthesis of disaccharides 9-22 using pNP -D-Galf 1 as donor and the linkag
regioisomers together with the isolated yields after two hours of reaction. 
Entry Acceptor Time (min) Product (yield, %) Overall yield (%) 
   (1→2) (1→3) (1→4) (1→6)  
1 4 (-D-Galp) 20 14 (41)   16 
                 (32) 
 73 15                        
2 5 (-D-Galp) 20 17 (27)   18 (25) 52 
3 6 (-D-Manp) 15 Mixture (1→2/3/4) (43) 19 (15) 58 
4 7 (-D-Manp) 25   20 (49) 21 (16) 65 
5 8 (-L-Rhap) 20   22 (38)  38 
 
 
 In order to elucidate binding modes of acceptors 2–7 in transglycosylation reactions, complexes of Araf51 with all putative 
transglycosylation products were subjected to molecular dynamics simulations (24 x 10 ns). Each putative product was docked into the 
active site by rigid fit of its Galf moiety onto the Araf moiety in the experimental structure. The pyranosyl and pNP-moieties were 
adjusted manually before the simulation. The results of simulations for disaccharides 11, 14, 17 and 18 are shown in figure 3. These 
selected products showed stable binding in the active site illustrated by low root-mean-square deviation (RMSD). The results also 
demonstrated that binding modes of (1→2) products are very similar. The pNP-moiety is oriented perpendicularly to the access of the 
active site. On the other hand, the pNP-moiety in 18 [-D-Galf-(1→6)--D-Galp], as an example of (1→6) product, is placed along the 
axis of the active site. The fact that the pNP-moiety may orient in different angles explains relatively broad acceptor specificity. Most 
other putative products have shown high RMSD which indicate either inability of the product to bind into the active site or incorrect 
docking. Unfortunately, attempts to quantitatively predict acceptors preferences from molecular simulations or free-energy methods were 
not successful (not shown). 
 Among the disaccharides prepared throughout this part, several display a configuration reported from uncommon cell wall 
glycoconjugates of some pathogenic species. Galactofuranosyl residue connected to D-Glcp moiety through the (1→3)-linkage has been 
identified e.g. in Streptococcus species,34 the one with the (1→6)-linkage is reported from Escherichia coli K-12 strain.35 The (1→3)-
linkage to D-Galp was identified in Fibrobacter succinogenes36 or in the O-antigen repeating unit of Klebsiella pneumoniae.36 In 
Mycobacterium species37-40 and Pleisiomonas shigelloides,41 -D-Galf is connected to L-Rhap through the (1→4)-linkage. The sequence -D-Galf-(1→2)-D-Manp is present in many microorganisms, among the pathogens notably Cryphonectria parasitica42 or 
Trichoderma.43 -D-Galf-(1→3)-D-Manp is frequent in Aspergillus,44 Trypanosoma cruzi 12, 45 and Leishmania,11 -D-Galf-(1→6)-D-
Manp e.g. in Aspergillus,44 Leishmania11or Paraccidioides brasiliensis.46 
 
Fig. 3 Predicted binding modes of 11, 14, 17 and 18 by 10 ns molecular dynamics simulations. The figure shows predicted binding modes at the end of 
each simulation (left) and corresponding RMSD profiles (right). These were obtained by fitting protein Cα atoms and calculating RMSD for the product. 
g targets were prepared disaccharides 
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Conclusions 
A chemo-enzymatic synthesis of galactofuranosyl-containing disaccharides was proposed mediated by the thermophilic 
arabinofuranosidase Araf51. We have first demonstrated that a large excess of acceptor allowed overcoming the self-condensation side 
reaction. Secondly, transglycosylation products were obtained in the early stage of the biocatalyzed process and increased reaction times 
did not affect the target furanosyl-pyranoside disaccharides since the degree of hydrolysis of the latter remained very low. These factors 
together were fruitful from a synthetic point of view. Consequently, and with regard to the very good yields obtained with the assistance 
of the hydrolytic furanosidase Araf51, this chemo-enzymatic approach constitutes a very interesting alternative to multi-step chemical 
synthesis of various mimetics of biologically significant structures. The +1 sub-site of Araf51 was able to recognize simple 
glycopyranosides as acceptors, even a Rhap derivative and its 1C4 conformation. Amon
b
Experimental S
General remarks 
Prior to NMR analysis, fractions were exchanged in D2O (99.9% purity) at room temperature with intermediate freeze-drying, and then 
dissolved in 400 μL of D2O. 1H, 13C, COSY, HSQC, HMBC, TOCSY and NOESY NMR spectra were recorded at the Laboratory of 
NMR spectroscopy (ICT Prague, Czech Republic) on a Bruker 600 Avance spectrometer equipped with a cryoprobe at 600 MHz for 1H 
and 125 MHz for 13C, and on a Bruker ARX 400 at 4 units (ppm). Coupling constants J are given in Hz. 
 The HRMS were measured at the Centre Régional de Mesures Physiques de l’Ouest (CRMPO, Université de Rennes 1, France) with a 
MS/MS ZabSpec TOF Macromass using m-nitrobenzylic alcohol as a matrix and accelerated caesium ions for ionization and at the 
Laboratory of Mass Spectrometry (ICT Prague, Czech Republic) using a Q-TOF Micro (Waters, USA), where electrospray-ionisation 
mass spectra (ESI-MS) were recorded on samples dissolved in MeOH injected in a volume of 2-5 μL into a flow (100 μL.min-1) of 
MeOH. Sample cone voltage was 42 V and the source temperature was 150 °C. Measurements were performed in positive ([M+Na]+ ion 
detection) mode in the range of 100-1000 Da. Finally, at the Mass Spectrometry Group (Institute of Organic Chemistry and 
Biochemistry, Academy of Sciences of the Czech Republic) on LTQ-O
samples dissolved in MeOH/H2O (1:1), sample cone voltage was 40 V. 
 Thin layer chromatography (TLC) analyses were conducted on Kieselgel 60 F254 (Merck) plates with 0.2-mm layer thickness. Spots 
were visualized by UV (254 nm) and by exposure to 0.2% w/v orcinol in H2SO4 (20% v/v) in ethanol. For column chromatography, 
0 and 405 nm by operating software Biologic DuoFlow. Collected fractions were lyophilized (FreeZone Freeze Dry 
-D-Galp, pNP -D-Galp, pNP -D-Glcp, pNP -D-Glcp, pNP -D-Manp, pNP 
 of 
evaporated and lyophilized several times with intermediate dissolving in H2O, finally in D2O and subjected to structural 
C), 69.0 (4a-C), 62.7 
a]+ 486.12181; found 486.12173. 
-C), 67.5 (4a-C), 62.8 (6b-C), 60.1 (6a-C) ppm. HRMS (ESI): m/z calcd for C18H25O13NNa [M+Na]
+ 486.12181; found 
.0 (4a-C), 62.7 (6b-C), 60.3 (6a-C) ppm. 
either Si 60 (40-63 μm) Silica gel or pre-packed Chromabond®Flash RS 15 SiOH columns (Macherey-Nagel) were used. 
 Gel permeation chromatography was performed on P-2 Bio-Gel (Bio-Rad) using FPLC system consisting of a solvent delivery system 
Biologic F40 DuoFlow, Biologic QuadTec UV-Vis Detector and Biologic BioFrac Fraction Collector (all Bio-Rad). Deionized filtrated 
(0.22 μm PVDF membrane, Millipore) water was used as a mobile phase with a flow rate of 0.15 mL.min-1. Separation was monitored by 
UV absorbance at 28
System, Labconco). 
 Recombinant arabinofuranosidase Araf51 was produces in E. coli and purified as already described.47 The hydrolytic activity toward 
p-nitrophenyl pyranosides was tested by incubation of the solution of enzyme (obtained after affinity Ni-NTA chromatography and 
exchanged to 50mM PBS pH 7.4 by PD10 gel chromatography) with individual glycopyranosides (5mM) in 50 mM potassium phosphate 
buffer pH 7.4 at 60 °C. The release of p-nitrophenolate was continuously measured at 405 nm (Microplate Spectrophotomerer 
PowerWave XS/XS2, BioTek) and data evaluated with Gen5 Data Analysis Software (BioTek). The synthesis of pNP -D-Galf is 
described in Supporting Information for this artcile. pNP -D-Manp and pNP -L-Rhap are commercially available. 
General procedure for the transglycosylation reactions 
Prior to preparative-scale reactions, the time-course analyses were performed in the analytical scale (5 μmol of individual pNP 
pyranosides, 0.5 μmol of pNP -D-galactofuranoside and 36 U of Araf51 in 100 μL of 50 mM PBS pH 7.4). The reaction was monitored 
by TLC (7:2:2 EtOAc/AcOH/H2O). Preparative-scale reactions were performed at 60 °C by incubation of the pNP -D-galactofuranoside 
(20 mg, 66 μmol; or 10 mg, 33 μmol) with individual pNP pyranosides (200 mg, 660 μmol for pNP D-Glcp and pNP D-Galp; 100 mg, 
330 μmol for pNP D-Manp and pNP L-Rhap) and 4800 U of Araf51 (for reactions with pNP D-Glcp and pNP D-Galp) or 2400 U of 
Araf51 (for reactions with pNP D-Manp and pNP L-Rhap) in 50 mM PBS pH 7.4 in a total volume with regard to the solubility
substrates: 5 mL (reactions with - and -D-Galp and -D-Glcp) or 10 mL (-D-Glcp and - and -D-Manp) or 15 mL (-L-Rhap). 
 Based on the results from analytical-scale reactions, individual reaction proceeded for 20 min with exception for -D-Manp (15 min) 
and -D-Manp (25 min) to obtain the maximum ratio of transglycosylation/hydrolysis. The reactions were stopped by enzyme 
denaturation at 100 °C for 10 min. The reactions products were repeatedly separated by silica gel flash chromatography using EtOAc-
AcOH-H2O in ratios from 15:1:1 to 40:1:1. Separations were monitored by TLC, fractions corresponding to individual regioisomers were 
collected, 
analyses. 
p-Nitrophenyl -D-galactofuranosyl-(1→2)--D-glucopyranoside (9) 
This compound was obtained according to the described general procedure by incubation of 20 mg (66 μmol) of 1 with 200 mg (660 
μmol) of pNP -D-glucopyranoside 2 in the presence of 4800 U of Araf51 and was isolated in 44% yield (13.3 mg) after purification. 
TLC: Rf = 0.45 (AcOEt/AcOH/H2O, 7/2/2). 
1H NMR (400 MHz, D2O):  = 8.19 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.23 (d, 2H, J = 9.2 Hz, 
Ho, C6H4), 5.87 (d, 1H, J = 3.6 Hz, 1a-H), 5.08 (d, 1H, J = 2.0 Hz, 1b-H), 4.07 (dd, 1H, J = 2.0, 4.2 Hz, 2b-H), 3.93 (dd, 1H, J = 4.2, 6.8 
Hz, 3b-H), 3.92 (dd, 1H, J = 9.0, 9.8 Hz, 3a-H), 3.70 (dd, 1H, J = 3.6, 9.8 Hz, 2a-H), 3.60-3.50 (m, 3H, 6a-H, 5a-H), 3.56 (dd, 1H, J = 
3.1, 6.8 Hz, 4b-H), 3.53-3.47 (m, 1H, 5b-H), 3.50 (dd, 1H, J = 9.0, 9.8 Hz, 4a-H), 3.10 (dd, 1H, J = 8.1, 11.5 Hz, 6b-H), 2.86 (dd, 1H, J = 
4.0, 11.5 Hz, 6’b-H) ppm. 13C NMR (100 MHz, D2O):  = 161.6 (Cipso C6H4), 142.7 (Cp C6H4), 126.1 (Cm C6H4), 116.7 (Co C6H4), 
109.5 (1b-C), 96.3 (1a-C), 82.6 (4b-C), 81.1 (2b-C), 79.3 (2a-C), 76.1 (3b-C), 72.4 (5a-C), 71.5 (3a-C), 69.7 (5b-
(6b-C), 60.1 (6a-C) ppm. HRMS (ESI): m/z calcd for C18H25O13NNa [M+N
p-Nitrophenyl -D-galactofuranosyl-(1→3)--D-glucopyranoside (10) 
This compound was obtained according to the described general procedure by incubation of 1 (20 mg, 66 μmol) with pNP -D-
glucopyranoside 2 (200 mg, 660 μmol) in the presence of 4800 U of Araf51. It was isolated in 34% yield (10.5 mg). TLC: Rf = 0.5 
(AcOEt/AcOH/H2O, 7/2/2). 
1H NMR (400 MHz, D2O):  = 8.12 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.18 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.70 
(d, 1H, J = 3.5 Hz, 1a-H), 5.24 (d, 1H, J = 1.5 Hz, 1b-H), 4.10 (dd, 1H, J = 1.5, 3.5 Hz, 2b-H), 4.03-3.99 (m, 2H, 3b-H, 4b-H), 3.96 (dd, 
1H, J = 9.2, 9.6 Hz, 3a-H), 3.80 (dd, 1H, J = 3.5, 9.6 Hz, 2a-H), 3.76 (ddd, 1H, J = 3.2, 4.4, 7.6 Hz, 5b-H), 3.67-3.57 (m, 5H, 6a-H, 6’a-
H, 6b-H, 6’b-H, 5a-H), 3.48 (dd, 1H, J = 9.2, 9.6 Hz, 4a-H) ppm. 13C NMR (100 MHz, D2O):  = 161.1 (Cipso C6H4), 141.9 (Cp C6H4), 
125.7 (Cm C6H4), 116.4 (Co C6H4), 108.3 (1b-C), 96.6 (1a-C), 82.9 (4b-C), 81.2 (2b-C), 79.4 (3a-C), 76.7 (3b-C), 72.7 (5a-C), 70.8 (2a-
C), 70.6 (5b
486.12160. 
p-Nitrophenyl -D-galactofuranosyl-(1→2)--D-glucopyranoside (11) 
This compound was obtained according to the described general procedure by incubating 1 (20 mg, 66 μmol) with pNP -D-
glucopyranoside 3 (200 mg, 660 μmol) in the presence of 4800 U of Araf51, and was isolated in 26% yield (7.9 mg). TLC: Rf = 0.4 
(AcOEt/AcOH/H2O, 7/2/2). 
1H NMR (400 MHz, D2O):  = 8.18 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.17 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.28 
(d, 1H, J = 7.2 Hz, 1a-H), 5.26 (d, 1H, J = 1.4 Hz, 1b-H), 4.03 (dd, 1H, J = 1.4, 2.5 Hz, 2b-H), 3.94-3.90 (m, 2H, 3b-H, 4b-H), 3.81 (dd, 
1H, J = 5.7, 12.4 Hz, 6a-H), 3.70-3.65 (m, 2H, 5b-H, 2a-H), 3.65 (dd, 1H, J = 9.5, 9.5 Hz, 3a-H), 3.64 (dd, 1H, J = 2.2, 12.4 Hz, 6’a-H), 
3.59-3.55 (m, 1H, 5a-H), 3.44 (dd, 1H, J = 4.3, 11.6 Hz, 6b-H), 3.43 (t, 1H, J = 9.5 Hz, 4a-H), 3.39 (dd, 1H, J = 7.3, 11.6 Hz, 6’b-H) 
ppm. 13C NMR (100 MHz, D2O):  = 161.6 (Cipso C6H4), 142.7 (Cp C6H4), 126.1 (Cm C6H4), 116.5 (Co C6H4), 108.3 (1b-C), 98.1 (1a-
C), 83.7 (4b-C), 81.0 (2b-C), 78.2 (2a-C), 76.7 (3b-C), 76.1 (5a-C), 75.6 (3a-C), 70.8 (5b-C), 69
HRMS (ESI): m/z calcd for C18H25O13NNa [M+Na]
+ 486.12181; found 486.12173. 
6 (5b-C), 67.7 (4a-C), 62.8 (6b-C), 60.5 (6a-C) ppm. HRMS 
. 
.8 (5b-C), 69.4 (4a-C), 66.3 (6a-C), 62.7 (6b-C) ppm. HRMS (ESI): m/z calcd for C18H25O13NNa 
0 (4a-C), 68.0 (3a-C), 62.6 (6b-
86.12181; found 486.12163. 
3a-C), 67.8 (2a-C), 62.7 (6b-C), 61.3 (6a-C) ppm. HRMS (ESI): m/z calcd for C18H25O13NNa [M+Na]
+ 486.12181; 
.6 (5b-C), 66.9 
NNa [M+Na]+ 486.12181; found 486.12162. 
p-Nitrophenyl -D-galactofuranosyl-(1→3)--D-glucopyranoside (12) 
This disaccharide was prepared as described in the general procedure starting from donor 1 (20 mg, 66 μmol) and pNP -D-
glucopyranoside 3 (200 mg, 660 μmol) in the presence of 4800 U of Araf51. The target compound 12 was isolated in 25% yield (7.6 mg) 
after purification. TLC: Rf = 0.48 (AcOEt/AcOH/H2O, 7/2/2). 
1H NMR (400 MHz, D2O):  = 8.18 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.17 
(d, 2H, J = 9.2 Hz, Ho, C6H4), 5.26 (d, 1H, J = 1.7 Hz, 1b-H), 5.21 (d, 1H, J = 7.6 Hz, 1a-H), 4.10 (dd, 1H, J = 1.7, 3.3 Hz, 2b-H), 4.02 
(dd, 1H, J = 3.8, 6.4 Hz, 4b-H), 4.01 (ddd, 1H, J = 0.4, 3.3, 6.4 Hz, 3b-H), 3.87-3.84 (m, 1H, 6a-H), 3.77-3.72 (m, 1H, 5b-H), 3.72-3.68 
(m, 1H, 3a-H), 3.70-3.66 (m, 2H, 2a-H, 6’a-H), 3.66-3.57 (m, 2H, 5a-H, 6b-H), 3.61-3.55 (m, 1H, 6’b-H), 3.49 (dd, 1H, 4a-H) ppm. 13C 
NMR (100 MHz, D2O):  = 161.6 (Cipso C6H4), 142.7 (Cp C6H4), 126.1 (Cm C6H4), 116.5 (Co C6H4), 108.1 (1b-C), 99.2 (1a-C), 83.0 
(4b-C), 81.5 (2a-C), 81.1 (2b-C), 76.6 (3b-C), 76.0 (5a-C), 72.8 (3a-C), 70.
(ESI): m/z calcd for C18H25O13NNa [M+Na]
+ 486.12181; found 486.12171
p-Nitrophenyl -D-galactofuranosyl-(1→6)--D-glucopyranoside (13) 
This compound was synthesized as described in the general procedure using 1 (20 mg, 66 μmol), pNP -D-glucopyranoside 3 (200 mg, 
660 μmol), and 4800 U of Araf51. The desired disaccharide 13 was isolated in 30% yield (9.2 mg). TLC: Rf = 0.4 (AcOEt/AcOH/H2O, 
7/2/2). 1H NMR (600 MHz, D2O):  = 8.22 (d, 2H, J = 9.1 Hz, Hm, C6H4), 7.21 (d, 2H, J = 9.1 Hz, Ho, C6H4), 5.22 (d, 1H, J = 2.7 Hz, 
1a-H), 4.94 (d, 1H, J = 1.5 Hz, 1b-H), 4.04-3.97 (m, 2H, 6a-H, 2b-H), 4.98 (dd,1H, J = 3.4, 6.2 Hz, 3b-H), 3.90-3.86 (m, 1H, 4b-H), 
3.80-3.71 (m, 3H, 5a-H, 5b-H, 6’a-H), 3,57-3.48 (m, 5H, 3a-H, 2a-H, 6b-H, 6’b-H, 4a-H) ppm; 13C NMR (125 MHz, D2O):  = 161.6 
(Cipso C6H4), 142.7 (Cp C6H4), 126.1 (Cm C6H4), 116.5 (Co C6H4), 107.9 (1b-C), 99.3 (1a-C), 83.0 (4b-C), 81.0 (2b-C), 76.8 (3b-C), 
75.3 (3a-C), 75.2 (5a-C), 72.7 (2a-C), 70
[M+Na]+ 486.12181; found 486.12172. 
p-Nitrophenyl -D-galactofuranosyl-(1→2)--D-galactopyranoside (14) 
This compound was obtained according to the general procedure starting from donor 1 (20 mg, 66 μmol), acceptor 4 (200 mg, 660 μmol) 
and 4800 U of Araf51. Compound 14 was isolated in 41% yield (12.6 mg). TLC: Rf = 0.4 (AcOEt/AcOH/H2O, 7/2/2). 
1H NMR (400 
MHz, D2O):  = 8.19 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.23 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.89 (d, 1H, J = 3.2 Hz, 1a-H), 5.08 (s, 1H, 1b-
H), 4.10 (dd, 1H, J = 3.3, 10.4 Hz, 3a-H), 4.07 (dd,1H, J = 2.1, 4.3 Hz, 2b-H), 3.99 (dd, 1H, J = 2.0, 3.3 Hz, 4a-H), 3.93 (ddd, 1H, J = 
0.7, 4.3, 6.9 Hz, 3b-H), 3.91 (dd, 1H, J = 3.7, 10.3 Hz, 2a-H), 3.89 (ddd, 1H, J = 1.9, 4.7, 7.7 Hz, 5a-H), 3.67-3.57 (m, 2H, 6a-H, 6’a-H), 
3.56 (dd, 1H, J = 2.9, 6.9 Hz, 4b-H), 3.52 (ddd, 1H, J = 2.9, 4.2, 8.2 Hz, 5b-H), 3.42 (dd, 1H, J = 4.0, 6.4 Hz, 6b-H), 3.11 (dd, 1H, J = 
8.0, 11.2 Hz, 6’b-H) ppm. 13C NMR (100 MHz, D2O):  = 161.6 (Cipso C6H4), 142.7 (Cp C6H4), 126.2 (Cm C6H4), 116.8 (Co C6H4), 
109.7 (1b-C), 96.6 (1a-C), 82.5 (4b-C), 81.2 (2b-C), 76.2 (2a-C and 3b-C), 71.8 (5a- C), 69.6 (5b-C), 69.
C), 60.8 (6a-C) ppm. HRMS (ESI): m/z calcd for C18H25O13NNa [M+Na]
+ 4
p-Nitrophenyl -D-galactofuranosyl-(1→3)--D-galactopyranoside (15) 
The disaccharide 15 was obtained according to the described general procedure by incubation of donor 1 (20 mg, 66 μmol) with acceptor 
4 (200 mg, 660 μmol) in the presence of 4800 U of Araf51, and was isolated in regioisomeric mixture with 16 in 32% yield (9.9 mg). 
According to the 1H NMR signal integration, it was obtained in 18% yield. TLC: Rf = 0.48 (AcOEt/AcOH/H2O, 7/2/2). 
1H NMR (400 
MHz, D2O):  = 8.19 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.23 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.74 (d, 1H, J = 3.8 Hz, 1a-H), 5.12 (d, 1H, J = 
2.1 Hz, 1b-H), 4.10 (dd, 1H, J = 3.7, 10.2 Hz, 3a-H), 4.07 (dd,1H, J = 2.2, 4.7 Hz, 2b-H), 4.02 (dd, 1H, J = 1.3, 3.0 Hz, 4a-H), 3.97 (dd, 
1H, J = 3.7, 10.4 Hz, 2a-H), 3.95 (dd, 1H, J = 4.4, 7.1 Hz, 3b-H), 3.92-3.87 (m, 1H, 5a-H), 3.85 (dd, 1H, J = 3.7, 7.1 Hz, 4b-H), 3.72-
3.67 (m, 1H, 5b-H), 3.57-3.50 (m, 4H, 6a-H, 6’a-H, 6b-H, 6’b-H) ppm; 13C NMR (100 MHz, D2O):  = 161.6 (Cipso C6H4), 142.7 (Cp 
C6H4), 126.2 (Cm C6H4), 116.8 (Co C6H4), 108.9 (1b-C), 96.6 (1a-C), 82.2 (4b-C), 81.4 (2b-C), 76.1 (3b-C), 75.6 (4a-C), 71.9 (5a-C), 
70.1 (5b-C), 69.6 (
found 486.12161. 
p-Nitrophenyl -D-galactofuranosyl-(1→4)--D-galactopyranoside (16) 
This compound was synthesized according to the described general procedure starting from 1 (20 mg, 66 μmol), pNP -D-
galactopyranoside 4 (200 mg, 660 μmol), 4800 U of Araf51, and was isolated in regioisomeric mixture with 15 in 32% yield (9.9 mg). 
According to the 1H NMR signal integration, this compound was obtained in 14% yield. TLC: Rf = 0.5 (AcOEt/AcOH/H2O, 7/2/2). 
1H 
NMR (400 MHz, D2O):  = 8.19 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.23 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.75 (d, 1H, J = 3.2 Hz, 1a-H), 5.15 
(d, 1H, J = 1.8 Hz, 1b-H), 4.10 (dd, 1H, J = 1.8, 3.6 Hz, 2b-H), 4.09-4.02 (m,2H,  4a-H, 3a-H), 4.03 (dd, 1H, J = 3.3, 10.4 Hz, 2a-H), 
3.96 (ddd, 1H, J = 0.9, 3.4, 6.7 Hz, 3b-H), 3.94 (dd, 1H, J = 4.0, 6.6, 4a-H), 3.90-3.86 (m, 1H, 5a-H), 3.74-3.68 (m, 1H, 5b-H), 3.58-3.52 
(m, 4H, 6a-H, 6’a-H, 6b-H, 6’b-H) ppm; 13C NMR (100 MHz, D2O):  = 161.6 (Cipso C6H4), 142.7 (Cp C6H4), 126.2 (Cm C6H4), 116.8 
(Co C6H4), 109.2 (1b-C), 96.6 (1a-C), 82.7 (4b-C), 81.4 (2b- C), 76.7 (3b-C), 72.0 (3a-C), 71.9 (5a-C), 71.9 (5a-C), 70
(2a-C), 62.6 (6b-C), 60.8 (6a-C) ppm. HRMS (ESI): m/z calcd for C18H25O13
p-Nitrophenyl -D-galactofuranosyl-(1→2)--D-galactopyranoside (17) 
The disaccharide was synthesized as described in the general procedure incubating furanosyl donor 1 (20 mg, 66 μmol) with pNP -D-
galactopyranoside 5 (200 mg, 660 μmol) in the presence of 4800 U of Araf51, and was isolated in 27% yield (8.1 mg). TLC: Rf = 0.4 
(AcOEt/AcOH/H2O, 7/2/2). 
1H NMR (400 MHz, D2O):  = 8.18 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.17 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.25 
(d, 1H, J = 1.5 Hz, 1b-H), 5.24 (d, 1H, J = 7.5 Hz, 1a-H), 4.05 (dd, 1H, J = 2.9, 1.5 Hz, 2b-H), 3.95 (dd,1H, J = 2.9, 5.8 Hz, 3b-H), 3.96-
3.91 (m, 1H, 5a-H), 3.91 (dd, 1H, J = 4.1, 5.8 Hz, 4b-H), 3.88 (dd, 1H, J = 7.5, 9.7 Hz, 2a-H), 3.84-3.78 (m, 2H, 3a-H, 4a-H), 3.73-3.67 
(m, 3H, 5b-H, 6a-H, 6’a-H), 3.45 (dd, 1H, J = 4.4, 11.7 Hz, 6b-H), 3.39 (dd, 1H, J = 7.3, 11.7 Hz, 6’b-H) ppm. 13C NMR (100 MHz, 
D2O):  = 161.9 (Cipso C6H4), 142.6 (Cp C6H4), 125.9 (Cm C6H4), 116.4 (Co C6H4), 108.4 (1a-C), 98.5 (1b-C), 83.5 (4a-C), 81.0 (2a-C), 
76.7 (3a-C), 76.4 (2b-C), 75.5 (4b-C), 72.6 3b-C), 70.8 (5a-C), 68.4 (5b-C), 62.6 (6a-C), 60.6 (6b-C) ppm. HRMS (ESI): m/z calcd for 
.2 (2a-C), 68.5 (4a-C), 66.9 (6a-C), 62.5 (6b-C) ppm. HRMS (ESI): m/z calcd for C18H25O13NNa [M+Na]
+ 486.12181; 
2.5 (4b-C), 81.1 (2b-C), 76.5 (3b-C), 
), 62.8 (6b-CH ) ppm. 
a-C), 62.6 (6b-C), 61.1 (5a-C), 60.3 (6a-C) ppm. HRMS (ESI): 
, 80.9 (2b-C), 76.8 (3b-C), 
), 62.7 (6b-CH2) ppm.  
.9 (2a-C), 68.2 (5a-C), 
) ppm. HRMS (ESI): m/z calcd for C18H25O12NNa [M+Na]
+ 470.12690; found 470.12665. 
C18H25O13NNa [M+Na]
+ 486.12181; found 486.12190. 
p-Nitrophenyl -D-galactofuranosyl-(1→6)--D-galactopyranoside (18) 
This compound was prepared according to the described general procedure by incubation of 1 (20 mg, 66 μmol) with of pNP -D-
galactopyranoside 5 (200 mg, 660 μmol) in the presence of 4800 U of Araf51, and was isolated in 25% yield (7.6 mg). TLC: Rf = 0.4 
(AcOEt/AcOH/H2O, 7/2/2). 
1H NMR (400 MHz, D2O):  = 8.18 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.17 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.12 
(d, 1H, J = 7.6 Hz, 1a-H), 4.90 (dd, 1H, J = 1.2, 0.6 Hz, 1b-H), 4.00 (ddd, 1H, J = 0.9, 3.8, 8.4 Hz, 4a-H), 3.97 (d, 1H, J = 1.2 Hz, 2b-H), 
3.96 (ddd, 1H, J = 3.3, 0.6 Hz, 3b- H), 3.93 (dd, 1H, J = 0.9, 3.4 Hz, 4a-H), 3.91 (dd, 1H, J = 1.5, 4.4 Hz, 4b-H), 3.83 (dd, 1H, J = 3.8, 
11.6 Hz, 6a-H), 3.76 (dd, 1H, J = 7.6, 9.9 Hz, 2a-H), 3.73-3.72 (m, 1H, 5b-H), 3.71 (dd, 1H, J = 8.4, 11.6 Hz, 6’a-H), 3.70 (dd, 1H, J = 
3.4, 9.9 Hz, 3a-H), 3,63-3.57 (m, 1H, 6b-H), 3.56-3.51 (m, 1H, 6’b-H) ppm. 13C NMR (100 MHz, D2O):  = 161.6 (Cipso C6H4), 142.7 
(Cp C6H4), 126.1 (Cm C6H4), 116.5 (Co C6H4), 107.8 (1b-C), 99.8 (1a-C), 83.1 (4b-C), 82.0 (2b-C), 76.7 (3b-C), 74.5 (5a-C), 72.3 (3a-
C), 70.7 (5b-C), 70
found 486.12172. 
p-Nitrophenyl -D-galactofuranosyl-(1→6)--D-mannopyranoside (19) 
This compound was prepared according to the described general procedure by incubation of 1 (20 mg, 66 μmol) with of pNP -D-
mannopyranoside 6 (200 mg, 660 μmol) in the presence of 4800 U of Araf51, and was isolated in 15% yield (4.6 mg). 1H NMR (600 
MHz, D2O): δ = 8.22 (d, 2H, J = 9.3 Hz, Hm, C6H4), 7.23 (d, 2H, J = 9.3 Hz, Ho, C6H4), 5.71 (d, 1H, J = 1.7 Hz, 1a-H), 4.91 (d,1H, J = 
1.7 Hz, 1b-H), 4.14 (dd, 1H, J = 1.7, 3.4 Hz, 2a-H), 3.99 (dd, 1H, J = 3.4, 9.1 Hz, 3a-H), 3.91-3.82 (m, 3H, 5a-H, 2b-H, 3b-H), 3.72-3.62 
(m, 3H, 4a-H, 6a-H, 6a‘-H), 3.62-3.56 (m, 1H, 5b-H), 3.52-3.44 (m, 3H, 4b-H, 6b-H, 6a‘-H) ppm. 13C NMR (125 MHz, D2O): δ = 160.7 
(Cipso C6H4), 142.0 (Cp C6H4), 126.0 (Cm C6H4), 116.8 (Co C6H4), 108.1 (1b-C), 97.6 (1a-C), 8
73.2 (4a-C), 70.5 (5b-C), 70.2 (3a-C), 69.6 (2a-C), 67.3(6a-CH2), 66.7 (5a-C 2
p-Nitrophenyl -D-galactofuranosyl-(1→4)--D-mannopyranoside (20) 
This compound was obtained according to the general procedure by incubation of 1 (10 mg, 33 μmol) with mannopyranosidic acceptor 7 
(100 mg, 330 μmol) in the presence of 2400 U of Araf51, and was isolated in 49% yield (7.5 mg). TLC: Rf = 0.49 (AcOEt/AcOH/H2O, 
7/2/2). 1H NMR (400 MHz, D2O):  = 8.16 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.13 (d, 2H, J = 9.2 Hz, Ho, C6H4), 5.43 (s, 1H, 1a-H), 5.02 
(d, 1H, J = 1.80 Hz, 1b-H), 4.18 (d, 1H, J = 2.6 Hz, 2a-H), 4.06-4.03 (m, 2H, 4b-H, 3b-H), 4.02 (d, 1H, 2b-H), 3.87 (dd, 1H, J = 1.9, 12.2 
Hz, 6a-H), 3.79 (dd, 1H, J = 2.6, 9.2 Hz, 3a-H), 3.80-3.76 (m, 1H, 4a-H), 3.75-3.73 (m, 1H, 5b-H), 3.72 (dd, 1H, J = 4.5, 12.2 Hz, 6’a-
H), 3.63 (ddd, 1H, J = 1.9, 5.4, 9.5 Hz, 5a-H), 3.60 (d, 1H, J = 6.7, 11.9 Hz, 6b-H), 3.58 (dd, 1H, J = 4.1, 11.9 Hz, 6’b-H) ppm. 13C NMR 
(100 MHz, D2O):  = 161.5 (Cipso C6H4), 142.4 (Cp C6H4), 126.1 (Cm C6H4), 116.2 (Co C6H4), 108.0 (1b-C), 97.0 (1a-C), 82.8 (3b-C), 
81.0 (4b-C), 76.0 (2b-C), 74.6 (4a-C), 71.2 (3a-C), 70.5 (5b-C), 70.1 (2
m/z calcd for C18H25O13NNa [M+Na]
+ 486.12181; found 486.12204. 
p-Nitrophenyl -D-galactofuranosyl-(1→6)--D-mannopyranoside (21) 
This compound was prepared according to the described general procedure by incubation of 1 (20 mg, 66 μmol) with of pNP -D-
mannopyranoside 6 (200 mg, 660 μmol) in the presence of 4800 U of Araf51, and was isolated in 15% yield (4.9 mg). 1H NMR (600 
MHz, D2O): δ = 8.20 (d, 2H, J = 9.3 Hz, Hm, C6H4), 7.17 (d, 2H, J = 9.3 Hz, Ho, C6H4), 5.46 (br s, 1H, 1a-H), 4.95 (d, J = 4.4 Hz, 1H, 
1b-H), 4.18 (d, 1H, J = 3.0 Hz, 2a-H), 4.00-3.00 (m, 2H, 5a-H, 2b-H), 3.97 (dd, 1H, J = 3.5, 6.0 Hz, 3b-H), 3.91 (dd, 1H, J = 4.3, 6.0 Hz, 
4b-H), 3.76-3.63 (m, 5H, 3a-H, 4a-H, 5b-H, 6a-H, 6a‘-H), 3.60-3.53 (m, 2H, 6b-H, 6b‘-H) ppm. 13C NMR (125 MHz, D2O): δ = 161.5 
(Cipso C6H4), 142.5 (Cp C6H4), 126.1 (Cm C6H4), 116.3 (Co C6H4), 107.9(1b-C), 97.0 (1a-C), 83.1 (4b-C)
75.5 (4a-C), 72.5 (3a-C), 70.8 (5b-C), 70.2 (2a-C), 66.6 (5a-C), 66.6 (6a-CH2
p-Nitrophenyl -D-galactofuranosyl-(1→4)--L-rhamnopyranoside (22) 
This compound was obtained according to the described general procedure by incubation of pNP -D-galactofuranoside 1 (10 mg, 33 
μmol) with pNP -L-rhamnopyranoside 8 (100 mg, 330 μmol) in the presence of 2400 U of Araf51, and was isolated in 38% yield (5.5 
mg). TLC: Rf = 0.5 (AcOEt/AcOH/H2O, 7/2/2). 
1H NMR (400 MHz, D2O):  = 8.15 (d, 2H, J = 9.2 Hz, Hm, C6H4), 7.13 (d, 2H, J = 9.2 
Hz, Ho, C6H4), 5.55 (d, 1H, J = 1.2 Hz, 1a-H), 5.21 (d, 1H, J = 1.7 Hz, 1b-H), 4.06 (dd, 1H, J = 1.2, 3.4 Hz, 2a-H), 4.04 (dd, 1H, J = 1.8, 
3.9 Hz, 2b-H), 4.04-4.00 (m, 1H, 3a-H), 3.97 (dd, 1H, J = 3.9, 6.3 Hz, 3b-H), 3.87 (dd, J = 3.8, 6.3 Hz, 1H, 4b-H), 3.72 (ddd, J = 4.4, 4.5, 
7.2 Hz, 1H, 5b-H), 3.58 (dd, 1H, J = 4.4, 11.6 Hz, 6b-H), 3.59-3.55 (m, 1H5a-H), 3.57-3.53 (m, 1H, 4a-H), 3.54 (dd, 1H, J = 7.2, 11.6 
Hz, 6’b-H), 1.11 (d, 1H, J = 5.7 Hz, CH3) ppm. 
13C NMR (100 MHz, D2O):  = 161.3 (Cipso C6H4), 142.0 (Cp C6H4), 125.8 (Cm C6H4), 
116.2 (Co C6H4), 108.4 (1b-C), 97.5 (1a-C), 82.7 (4b-C), 81.5 (2b-C), 77.8 (4a-C), 70.4 (5b-C), 70.3 (3a-C), 69
62.7 (6a-C), 17.1 (6a-C
Molecular modeling 
All simulations were performed in Gromacs 4.5.5.48 Each system included one molecule of Araf51 (from the experimental structure, 
PDB I.D. 2C8N),49 one molecule of putative transglycosylation product, ~18 300 water molecules and 15 sodium counter-ions. Protein 
was modelled using Amber99SB force field,50 transglycosylation products were modelled using Glycam0651 (carbohydrates) and General 
Amber Force Field52 (pNP-moiety). Charges were calculated by RESP method on the basis of HF/6-31G*//HF/6-31G* wavefunction 
calculated for individual fragments in Gaussian 0353. Molecules of putative products were placed to the active site by 3D-alignment of 
the Galf moiety with the Araf moiety in the experimental structure. This was followed by manual adjustment of glycosidic bond torsions 
to avoid steric clashes. Finally, the system was minimized (3 000 steps of L-BFGS and 500 steps of steepest descent) and simulated by 
1 ns of equilibration and 10 ns of production simulation. Non-hydrogen atoms of the protein and Galf were restrained during the 
equilibration run by a harmonic restraint potential. 
and 7AMB13FR014). The authors are finally grateful to the 
GlycoOuest network, supported by the Région Bretagne and the Région Pays de la Loire. 
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